Crispr Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Crispr Therapeutics stock Target Raised by   Oppenheimer Holdings Inc. on 6/23/2020. In a note to investors, the firm issued a new target price of $89.00. The analysts previously had $80.00 target price. Oppenheimer Holdings Inc.’s price target would indicate a potential upside of 23.58% from the stock’s previous close.

Shares of Crispr Therapeutics traded down -$2.28 on Wednesday, reaching $73.09. 1418475 shares of the stock traded hands, compared to its average volume of 1014447. Shares of CRSP
Crispr Therapeutics were trading at $73.09 on Wednesday. The firm’s 50 day moving average is $$59.50 and its 200 day moving average is $53.76.Crispr Therapeutics  has a 12 month low of $71.59 and a 12 month high of $79.92. While on yearly highs and lows, Crispr Therapeutics today has traded high as $76.86 and has touched $71.59 on the downward trend.

Crispr Therapeutics Earnings and What to expect: 

Crispr Therapeutics last issued its earnings data on April 28th, 2020. The reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.10. The business earned $0.16 million during the quarter, compared to analyst estimates of $3.04 million. Its revenue for the quarter was down 52.1% on a year-over-year basis. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 100.5. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 3rd, 2020 based off prior year’s report dates.

Earnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.51) to ($5.22) per share. The P/E ratio of Crispr Therapeutics is 100.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.34. The P/E ratio of Crispr Therapeutics is 100.49, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.57. Crispr Therapeutics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 17.10%
  • On 6/1/2020 CEO Samarth Kulkarni Sell 17,275 at average share price of $64.68 which equates to $1,117,347.00 in money value.
  • On 5/20/2020 CEO Samarth Kulkarni Sell 10,693 at average price of  $65.28 with total value of : Not Data Available
  • On 5/19/2020 President Rodger Novak Sell 50,000 at average price of  $65.00 with total value of : $3,250,000.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Crispr Therapeutics

  • 6/20/2020 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2020 – Crispr Therapeutics had its “overweight” rating re-affirmed by analysts at Piper Sandler. They now have a $104.00 price target on the stock.
  • 6/19/2020 – Crispr Therapeutics had its price target raised by analysts at Roth Capital from $100.00 to $105.00. They now have a “buy” rating on the stock.
  • 6/15/2020 – Crispr Therapeutics had its price target raised by analysts at Canaccord Genuity from $80.00 to $84.00. They now have a “buy” rating on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by Oppenheimer Holdings Inc.: 

  • 6/23/2020 – Sunesis Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 6/23/2020 – Intersect ENT is now covered by analysts at Oppenheimer Holdings Inc.. They set a “market perform” rating on the stock.
  • 6/23/2020 – Baxter International is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating on the stock.
  • 6/23/2020 – Viewray had its “buy” rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $3.00 price target on the stock.
  • See More Analyst Rating at: RATING

Crispr Therapeutics (NASDAQ:CRSP) Moving Average Technical Analysis

5 day Moving Average is $$70.03 And 5 day price change is $9.10 (13.73%)  with average volume for 5 day average is 1,226,100. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $65.10 and 20 day price change is $9.03 (13.61%) and average 20 day moving volume is 938,745. 50 day moving average is $59.50  and 50 day price change is $29.36 ( 63.81%)  and with average volume for 50 days is : 943,240. 200 day moving average is $53.76  and 200 day price change is $29.58 (64.60%)  and with average volume for 200 days is : 973,534.

See More Analyst Rating at: RATING



Source link